Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Fred Lux

Neurology Bloomington, MN Medical Doctor

NPI 1982608535 CMS profile 676252

3601 Minnesota Dr Ste 200, Suite 200, Bloomington, MN 55435

Open in the dashboard

General payments

$19

1 record reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Through program year 2019, Fred Lux of Bloomington, MN is reported in the CMS Open Payments database as having received $19 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 2nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Fred Lux
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Fred Lux were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Fred Lux Neurology median Middle half National median
2019 $19 $474 $118–$2,177 $163
2020 $0 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program year 2019
  1. US WorldMeds, LLC $19 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Education $19 1 payment
Products named General payments · program year 2019
  1. APOKYN $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 67 drugs

Part D claims

2,495

Median for Neurology: 833

Drug cost

$830,817

Median for Neurology: $202,670

Branded share of claims

35.6%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rebif Interferon Beta-1a/Albumin Brand 14 $147,567
Copaxone Glatiramer Acetate Brand 21 $122,584
Avonex (4 Pack) Interferon Beta-1a Brand 12 $101,783
Glatopa Glatiramer Acetate Brand 32 $94,005
Nurtec Odt Rimegepant Sulfate Brand 70 $78,738
Aimovig Autoinjector Erenumab-Aooe Brand 89 $71,521
Teriflunomide Generic 16 $31,365
Emgality Pen Galcanezumab-Gnlm Brand 38 $28,013
Zonegran Zonisamide Brand 12 $27,799
Ubrelvy Ubrogepant Brand 14 $13,943

The 10 drugs with the highest cost, of 67 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$384,668

Of which drugs: $334,494

Medicare patients

319

Average age 71

Services billed

14,201

202 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 47%
Depression 37%
Ischemic heart disease 22%
Diabetes 20%
Alzheimer's or dementia 19%
Osteoporosis 18%
Chronic kidney disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record